116371-67-6 Usage
Description
2'-Deoxy-2',2'-difluoro-5'-cytidylic Acid, also known as Gemcitabine Monophosphate, is a gemcitabine derivative with antineoplastic properties. It is a white to off-white solid that has been developed for its potential use in cancer treatment. 2'-Deoxy-2',2'-difluoro-5'-cytidylic Acid is characterized by the presence of a deoxyribose sugar with a 2',2'-difluoro modification, which contributes to its unique chemical and biological properties.
Uses
Used in Pharmaceutical Industry:
2'-Deoxy-2',2'-difluoro-5'-cytidylic Acid is used as an antineoplastic agent for its cancer-fighting capabilities. It is particularly effective in the treatment of various types of cancer due to its ability to interfere with the synthesis of DNA and RNA, leading to the inhibition of cancer cell growth and proliferation.
Used in Cancer Research:
In the field of cancer research, 2'-Deoxy-2',2'-difluoro-5'-cytidylic Acid serves as a valuable compound for studying the mechanisms of action and potential applications in targeted cancer therapies. Its unique chemical structure allows researchers to explore new avenues for the development of more effective and selective antineoplastic agents.
Used in Drug Development:
2'-Deoxy-2',2'-difluoro-5'-cytidylic Acid is utilized in the development of novel drug formulations and delivery systems, aiming to improve the efficacy and safety of cancer treatments. Its chemical properties make it a promising candidate for the design of innovative therapeutic strategies, including combination therapies and targeted drug delivery approaches.
Check Digit Verification of cas no
The CAS Registry Mumber 116371-67-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,6,3,7 and 1 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 116371-67:
(8*1)+(7*1)+(6*6)+(5*3)+(4*7)+(3*1)+(2*6)+(1*7)=116
116 % 10 = 6
So 116371-67-6 is a valid CAS Registry Number.
116371-67-6Relevant articles and documents
Synthesis and antitumor activity of a heterodinucleotide of BVDU and gemcitabine
Cappellacci,Franchetti,Vita,Petrelli,Grifantini
, p. 460 - 468 (2008)
A heterodinucleotide comprising BVDU and Gemcitabine bound together by a 5′,5′-pyrophospate bridge (BVDUp2dFdC) has been synthesized and evaluated as antitumor agent against AH13 rat sarcoma cells. BVDUp2dFdC showed a cytotoxicity similar to that of Gemcitabine. Copyright Taylor & Francis Group, LLC.
Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy
Ding, Xiaoyi,Huang, Wei,Jiang, Chen,Li, Fuyou,Sun, Tao,Wang, Qingbing,Wang, Zhongmin,Wu, Zhiyuan,Zhu, Xingjun
, p. 2410 - 2417 (2020/04/08)
Gemcitabine (GEM) has been the recommended first-line drug for patients with pancreatic ductal adenocarcinoma cancer (PDAC) for the last twenty years. However, GEM-based treatment has failed in many patients because of the drug resistance acquired during
Efficient synthesis of gemcitabine 5′-O-triphosphate using gemcitabine 5′-O-phosphoramidate as an intermediate
Kaczmarek, Renata,Radzikowska, Ewa,Baraniak, Janina
supporting information, p. 1851 - 1854 (2014/08/18)
A new efficient approach for the synthesis of gemcitabine triphosphate has been developed. The method is based on the ring-opening reaction of 2-cyanoethoxy-2-oxo-1,3,2-oxathiaphospholane with protected gemcitabine in the presence of DBU. Subsequent treatment of gemcitabine monophosphate with DCC in the presence of ammonia provides gemcitabine 5′-O-phosphoramidate. Finally, this compound, on reaction with pyrophosphate, furnishes gemcitabine 5′-triphosphate in 50% yield. Georg Thieme Verlag Stuttgart. New York.